Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery

This cohort study evaluates the incidence of cataract surgery among patients receiving mirvetuximab soravtansine to treat ovarian cancer.

Corresponding Author: Jordyn F. Silverstein, MD, Division of Hematology and Oncology, University of California, Los Angeles, 757 Westwood Plaza, Los Angeles, CA 90095 (jsilverstein@mednet.ucla.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.